IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...
IntraBio’s Aqneursa receives European Commission’s marketing approval for treatment of Niemann-Pick Type C disease: Austin, Texas Saturday, January 24, 2026, 14:00 Hrs [IST] I ...
IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA(levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results